Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal
Published: March 09, 2026 by: Invezz
Sentiment: Positive
Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers.
Read More
Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal
Published: March 09, 2026 by: Invezz
Sentiment: Positive
Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers.
Read More
YieldMax® HIMS Option Income Strategy ETF (HIYY) Trading Halt
Published: March 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
MILWAUKEE, March 05, 2026 (GLOBE NEWSWIRE) -- Tidal Investments LLC (“Tidal”) announces that the YieldMax® HIMS Option Income Strategy ETF (NYSE Arca: HIYY) was halted to allow Tidal to evaluate the accuracy of the HIYY Net Asset Values per share (NAVs) published for March 2, 3, and 4, 2026. Tidal determined the NAV for HIYY was required to be restated on March 2 from $12.38 per share to $12.15 per share, on March 3 from $9.92 per share to $11.81 per share and on March 4 from $10.24 per share to $12.13 per share.
Read More
Hims and Hers Expands Its Technology Driven Consumer Health Platform
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its tech-driven care platform with data-led Labs testing, new menopause and testosterone services and global expansion into Canada.
Read More
Hims & Hers Health: Leaving GLP-1s Behind
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers (HIMS) remains a 'Strong Buy' at $16, with fair value estimated at $22 despite recent headwinds. International expansion via the $1.15B Eucalyptus acquisition and product diversification are key drivers, though margins will remain pressured. GLP-1 regulatory risks have intensified, but HIMS is pivoting to diversified growth pillars beyond weight loss.
Read More
Hims' pharmacy partner will reintroduce GLP-1 pill pulled from market, Endpoints News reports
Published: March 03, 2026 by: Reuters
Sentiment: Neutral
Hims & Hers Health's pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded weight‑loss pill through other healthcare providers after halting distribution following U.S. regulatory pushback, Endpoints News reported on Tuesday.
Read More
Carillon Eagle Small Cap Growth Fund Q4 2025 Portfolio Review
Published: March 02, 2026 by: Seeking Alpha
Sentiment: Positive
Coherent is expected to continue to benefit from a transition to products that enable faster throughput speeds, while prior constraints on manufacturing capacity appear to be alleviating. BrightSpring Health Services reported another strong quarter with both revenues and EBITDA up significantly, far outpacing its historical growth rate prior to going public in 2024. Varonis Systems, which provides data protection security software, delivered disappointing earnings results and an outlook below expectations.
Read More
Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
Published: March 02, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CLICK HERE TO PARTICIPATE. What Happened? On February 7, 2026, The New York Times re.
Read More
Hims expansion may not come in time for risky GLP-1 business
Published: March 02, 2026 by: Reuters
Sentiment: Negative
Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soon enough for investors who are growing impatient.
Read More
Hims & Hers Expands Digital Health and Global Platform Strategy
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS expands into labs, cancer screening, menopause and global markets, advancing its digital, subscription-driven healthcare platform and preventive care.
Read More
Law Offices of Howard G. Smith Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors
Published: February 27, 2026 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. IF YOU ARE A HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER, CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howard.
Read More
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making
Published: February 27, 2026 by: The Motley Fool
Sentiment: Positive
Hims & Hers offers direct-to-consumer healthcare in a digitally native manner. The company is profitable, and its subscriber base is growing.
Read More
HIMS vs. AMWL: Which Telehealth Stock Is the Better Investment Now?
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and Amwell are taking different paths in telehealth, but which stock offers the stronger opportunity today? Let's dive in.
Read More
Hims & Hers Health: The GLP-1 Party Is Over
Published: February 25, 2026 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health, Inc. is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. HIMS' reliance on compounded GLP-1 drugs has faltered, with regulatory headwinds and an SEC investigation clouding visibility and investor trust. Despite solid subscriber and revenue growth, margin compression and weak guidance highlight unsustainable marketing intensity and operational risks.
Read More
Hims & Hers Health: Great Vision, Now On Sale -- Here's Why I'm Upgrading
Published: February 24, 2026 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health, Inc. faces severe volatility, regulatory scrutiny, and legal risks, especially in its weight-loss drug segment, yet I maintain a cautious BUY rating. Q4 results showed revenue of $617.8M (+28% YoY) and adjusted EBITDA of $66.3M, but subscriber growth and Q1 guidance disappointed due to GLP-1 headwinds. International expansion and labs initiatives are key growth drivers, with management targeting $1B+ annual international revenue and $1.3B adjusted EBITDA by 2030.
Read More
Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Negative
HIMS reports an earnings beat and strong revenue growth in fourth-quarter 2025, but margin pressure and a softer outlook clouded the quarterly performance.
Read More
KDP Beats & HIMS Misses Sales, QCOM Gains on Upgrades
Published: February 24, 2026 by: Schwab Network
Sentiment: Neutral
Keurig Dr. Pepper (KDP) didn't fizzle out when it came to earnings, with Diane King Hall noting a beat Tuesday morning. Hims & Hers (HIMS) couldn't do the same as the telehealth company sees headwinds as subscribers shrink.
Read More
Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard
Published: February 24, 2026 by: 24/7 Wall Street
Sentiment: Negative
Shares of Hims & Hers Health ( NYSE:HIMS ) are trading lower this morning after yesterday's earnings, and the reason is straightforward: guidance.
Read More
Hims & Hers Accelerates AI Preventive Care and Platform Strategy
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Neutral
HIMS is accelerating AI-driven preventive care with new menopause, low testosterone and multi-cancer testing, deepening its personalized digital health platform.
Read More
Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?
Published: February 20, 2026 by: 24/7 Wall Street
Sentiment: Neutral
Hims & Hers Health ( NYSE:HIMS ) just made a bold move to take its personalized wellness platform global.
Read More
Hims & Hers to acquire Australian digital health firm Eucalyptus, expanding international footprint
Published: February 19, 2026 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS) announced on Thursday that it has entered a definitive agreement to acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion. The acquisition is expected to strengthen Hims & Hers' international presence and expand its personalized healthcare offerings.
Read More
Can Platform Strength Support Hims & Hers Stock Before Q4 Earnings?
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS fourth-quarter 2025 results are likely to benefit from new specialties and global expansion, but higher costs and GLP-1 scrutiny could cloud earnings.
Read More
Hims & Hers Health Stock Resumes Climb on Acquisition News
Published: February 19, 2026 by: Schaeffers Research
Sentiment: Positive
At last glance, shares of Hims & Hers Health Inc (NYSE:HIMS) are up 0.5% to trade at $15.91, after the wellness company announced its $1.15 billion acquisition of Australian digital health company Eucalyptus.
Read More
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings
Published: February 18, 2026 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings
Read More
Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month's 48% Selloff
Published: February 16, 2026 by: 24/7 Wall Street
Sentiment: Negative
Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30 as of February 13.
Read More
Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out for
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Negative
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Hims & Hers Strengthens Integrated Personalized Digital Care Platform
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5 million.
Read More
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin pressures raise concerns.
Read More
HIMS Selloff Creates De-Risked Entry
Published: February 11, 2026 by: Seeking Alpha
Sentiment: Negative
HIMS Selloff Creates De-Risked Entry
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Medical - Equipment & Services
- CEO Andrew Dudum
- Employees 1637